These subgroup analyses have shown that the ESCC patients with liver metastases and with higher PD‐L1 expression may derive more favorable PFS and OS from the addition of serplulimab than their counterparts with low PD‐L1 expression. Here, CD274 is linked to esophageal squamous cell carcinoma.